Validating Predictive Models and Biomarkers of Radiotherapy Toxicity to Reduce Side-Effects and Improve Quality of Life in Cancer Survivors
Lo scopo di questo studio internazionale è quello di cercare di prevedere quali tra i pazienti che ricevono radioterapia sono più soggetti di altri a riportare effetti collaterali
The aim of this report is to provide a final update on the outputs and dissemination activities of the REQUITE consortium.
The main achievement of REQUITE was completing an observational study, the largest of its kind, which is recognised as an exemplar of the type of multi-disciplinary, multinational work that can and should be carried out in the radiotherapy-related research field.
A core aim of the REQUITE project was to find and validate genetic predictors of radiotherapy side effects. To do this the project collected blood samples from each patient at the time they were recruited, before radiotherapy. The aim of this report is to report on the genotyping undertaken of blood samples collected in the observational study and processed by the CIGMR biobank.
The annual congress of ESTRO will take place 26-30 April 2019 in Milan, Italy. ESTRO 38 will offer all professionals of oncology the chance to share knowledge, practice and advances in the field, within the ever warm and dynamic environment of the ESTRO meetings. ‘Targeting optimal care, together’ will be the theme of ESTRO 38 and through these few, however impactful words, the Scientific and organising committees would like to put a spotlight on the multiprofessional and multidisciplinary aspect of our specialty. The theme also represents our strength: we are all working towards a common goal for improved patient outcomes, and this will be expressed throughout the scientific programme... See for more information the website